ArticleFrontiers in immunology2026
Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgA nephropathy (IgAN) exhibits a highly variable clinical course. As responses to immunosuppressive therapy remain inconsistent, reliable prognostic markers are critically required to identify patients who can show a good response to immunosuppressive treatments. Methods: This prospective cohort study enrolled adults with biopsy-proven IgAN from 2010-2020. Good prognosis was defined as a ≥50% reduction in the urine protein-to-creatinine ratio (uPCR) or <0.5 g/g with preserved estimated glomerular filtration rate 1 year after biopsy. Serum and urine cytokines/chemokines (TGF-β1, MCP-1, RANTES, and VEGF) and intrarenal CD45 Results: Among the 202 patients, 120 (59.4%) had a good prognosis and showed a significantly lower risk of end-stage kidney disease over a 10-year follow-up. Multivariable analyses identified immunosuppressive therapy, low histologic grade, lower uPCR, absence of hypertension, higher serum TGF-β1 levels, and reduced intrarenal CD45 Conclusions: Serum TGF-β1 and MCP-1 levels may serve as biomarkers of favorable prognosis among patients with IgAN receiving immunosuppressive therapy, whereas intrarenal CD20
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.